Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.31M Buy
17,422
+455
+3% +$156K 0.14% 163
2026
Q1
$5.97M Buy
16,967
+1,489
+10% +$531K 0.15% 148
2025
Q4
$5.07M Buy
15,478
+2,057
+15% +$653K 0.13% 172
2025
Q3
$3.79M Buy
13,421
+580
+5% +$168K 0.1% 215
2025
Q2
$3.59M Sell
12,841
-77
-0.6% -$21.8K 0.1% 204
2025
Q1
$4.02M Buy
12,918
+1,247
+11% +$368K 0.13% 170
2024
Q4
$3.04M Buy
+11,671
New +$3.46M 0.1% 204

Other funds holding AMGN

Cary Street Partners's AMGN Position: Q2 2026 in Review

Cary Street Partners increased its Amgen (AMGN) stake by 2.7% in Q2 2026, buying an estimated $156K and bringing the position to 17,422 shares worth $6.31M. The position accounts for 0.14% of the portfolio, ranked #163.

Cary Street Partners first reported a position in AMGN in Q4 2024 and has held it in 7 quarters since. 1,278 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Cary Street Partners held 17,422 shares of Amgen worth $6.31M as of Q2 2026.
  • Cary Street Partners bought 455 Amgen shares in Q2 2026, an estimated $156K.
  • Amgen made up 0.14% of Cary Street Partners's portfolio in Q2 2026, its #163 holding.
  • Cary Street Partners first reported a position in Amgen in Q4 2024 and has held it in 7 quarters since.
  • 1,278 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.